RT Journal Article
SR Electronic
T1 Demethylation and upregulation of an oncogene post hypomethylating treatment
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.21.20157776
DO 10.1101/2020.07.21.20157776
A1 Liu, Yao-Chung
A1 Fabiani, Emiliano
A1 Kwon, Junsu
A1 Gao, Chong
A1 Falconi, Giulia
A1 Valentini, Lia
A1 Gurnari, Carmelo
A1 Liu, Yanjing V.
A1 Jones, Adrianna I.
A1 Yang, Junyu
A1 Yang, Henry
A1 Thoms, Julie A. I.
A1 Unnikrishnan, Ashwin
A1 Pimanda, John E.
A1 Pan, Rongqing
A1 Voso, Maria Teresa
A1 Tenen, Daniel G.
A1 Chai, Li
YR 2020
UL http://medrxiv.org/content/early/2020/07/26/2020.07.21.20157776.abstract
AB While hypomethylating agents (HMA) are currently used to treat myelodysplastic syndrome (MDS) patients, their effects on reactivation and/or upregulation of oncogenes have not been previously described. SALL4 is a known oncogene that plays an important role in MDS. In this study, we examined the relationship between SALL4 methylation and expression, and evaluated changes of SALL4 expression and their prognostic value in MDS patients undergoing HMA treatment. In no/low-SALL4 expressing leukemic cell lines, we identified that demethylation of a critical CpG region was associated with increased SALL4 expression, and HMA treatment led to demethylation of this region and upregulation of SALL4. In MDS patients, we observed SALL4 upregulation after four cycles of azacytidine (AZA) treatment in 40% of the cases. Significantly, patients in the responder group with SALL4 upregulation had the worst outcome. This is the first study focusing on demethylation and upregulation of an oncogene after HMA treatment. Our data indicate that MDS patients receiving HMA treatment should be monitored for upregulation of oncogenes such as SALL4 for poor outcome.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT number 2010-019673-15Funding StatementThis study was supported by Myeloid Neoplasms Research Venture AIRC MYNERVA, National Institutes of Health; Singapore Ministry of Health's National Medical Research Council; Leukemia and Lymphoma Society and Xiu Research FundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:BM samples were obtained from 37 newly diagnosed MDS patients enrolled in the BMT-AZA trial (EudraCT number 2010-019673-15). The study was approved by the IRB at University of Roma Tor VergataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data in the main manuscript and supplementary data are available on request